Whole-genome copy-number analysis identifies new leads for chromosomal aberrations involved in the oncogenesis and metastastic behavior of uveal melanomas

Melanoma Research

Volumn 25, Issue 3, 2014, Pages 200-209

  Van Engen Van Grunsven, Adriana C H ^a   Baar, Marjolein P ^a   Pfundt, Rolph ^b   Rijntjes, Jos ^a   Küsters Vandevelde, Heidi V N ^c   Delbecq, Ann Laure ^a   Keunen, Jan E ^a   Klevering, Jeroen B ^a   Wesseling, Pieter ^a,c,d   Blokx, Willeke A M ^a   Groenen, Patricia J T A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Human Genetics ^*  (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BAP; Chromothripsis; Copy number variations; GNA11; GNAQ; OncoScan analysis; Uveal melanoma

Indexed keywords

PROTEIN; PROTEIN BAP1; PROTEIN GNA11; PROTEIN GNAQ; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CHROMOSOME 1; CHROMOSOME 2P; CHROMOSOME 3; CHROMOSOME 6; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA SEQUENCE; ENUCLEATION; FEMALE; GENE MUTATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS; MIDDLE AGED; MONOSOMY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATION RATE; PANCREAS CARCINOMA; PANCREAS METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; UVEA MELANOMA; BIOLOGICAL MODEL; CHOROID; CILIARY BODY; FOLLOW UP; GENE TRANSLOCATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MELANOMA; METABOLISM; MUTATION; NETHERLANDS; PATHOLOGY; PROGNOSIS; SECONDARY; UNIVERSITY HOSPITAL; UVEAL NEOPLASMS;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; CARCINOGENESIS; CHOROID; CHROMOSOME ABERRATIONS; CILIARY BODY; DNA COPY NUMBER VARIATIONS; FEMALE; FOLLOW-UP STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MELANOMA; MIDDLE AGED; MODELS, GENETIC; MUTATION; NETHERLANDS; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSLOCATION, GENETIC; UVEAL NEOPLASMS;

EID: 84983508958     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000152     Document Type: Article

References (38)

1. Shields CL, Shields JA. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol 2009; 27:122-133.
2. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44:4651-4659.
3. Coupland SE, Campbell I, Damato B. Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability. Ophthalmology 2008; 115:1778-1785.
4. Folberg R, Pe'er J, Gruman LM, Woolson RF, Jeng G, Montague PR, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol 1992; 23:1298-1305.
5. Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012; 119:1596-1603.
6. Gill HS, Char DH. Uveal melanoma prognostication: from lesion size and cell type to molecular class. Can J Ophthalmol 2012; 47:246-253.
7. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64:7205-7209.
8. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998; 16:1097-1112.
9. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330:1410-1413.
10. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, Harbour JW. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49:5230-5234.
11. Bauer J, Kilic E, Vaarwater J, Bastian BC, Garbe C, de Klein A. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer 2009; 101:813-815.
12. Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V, et al. Mutational profile of GNAQQ209 in human tumors. PLoS One 2009; 4: e6833.
13. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457:599-602.
14. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363:2191-2199.
15. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002; 296:1636-1639.
16. Van Raamsdonk CD, Barsh GS, Wakamatsu K, Ito S. Independent regulation of hair and skin color by two G protein-coupled pathways. Pigment Cell Melanoma Res 2009; 22:819-826.
17. Van Raamsdonk CD, Fitch KR, Fuchs H, de Angelis MH, Barsh GS. Effects of G-protein mutations on skin color. Nat Genet 2004; 36:961-968.
18. Daniels AB, Lee JE, MacConaill LE, Palescandolo E, Van Hummelen P, Adams SM, et al. High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest Ophthalmol Vis Sci 2012; 53:6991-6996.
19. Küsters-Vandevelde HV, Klaasen A, Küsters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, et al. Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 2010; 119:317-323.
20. Hawkes JE, Campbell J, Garvin D, Cannon-Albright L, Cassidy P, Leachman SA. Lack of GNAQ and GNA11 germ-line mutations in familial melanoma pedigrees with uveal melanoma or blue nevi. Front Oncol 2013; 3:160.
21. Wang Y, Cottman M, Schiffman JD. Molecular inversion probes: a novel microarray technology and its application in cancer research. Cancer Genet 2012; 205:341-355.
22. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011; 144:27-40.
23. Forment JV, Kaidi A, Jackson SP. Chromothripsis and cancer: causes and consequences of chromosome shattering. Nat Rev Cancer 2012; 12:663-670.
24. Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood 2011; 118:675-678.
25. Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012; 148:59-71.
26. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, et al. Subgroup-specific structural variation across 1, 000 medulloblastoma genomes. Nature 2012; 488:49-56.
27. Patel M, Smyth E, Chapman PB, Wolchok JD, Schwartz GK, Abramson DH, Carvajal RD. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res 2011; 17:2087-2100.
28. Ewens KG, Kanetsky PA, Richards-Yutz J, Purrazzella J, Shields CL, Ganguly T, Ganguly A. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma. Invest Ophthalmol Vis Sci 2014; 55:5160-5167.
29. Griewank KG, van de Nes J, Schilling B, Moll I, Sucker A, Kakavand H, et al. Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Mod Pathol 2014; 27:175-183.
30. Hirsch D, Kemmerling R, Davis S, Camps J, Meltzer PS, Ried T, Gaiser T. Chromothripsis and focal copy number alterations determine poor outcome in malignant melanoma. Cancer Res 2013; 73:1454-1460.
31. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997; 19:22-28.
32. Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci 2009; 50:3048-3055.
33. White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998; 83:354-359.
34. Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 2013; 45:133-135.
35. Martin M, Maßhöfer L, Temming P, Rahmann S, Metz C, Bornfeld N, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 2013; 45:933-936.
36. Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma [review]. Curr Opin Ophthalmol 2014; 25:234-239.
37. Maat W, Jordanova ES, van Zelderen-Bhola SL, Barthen ER, Wessels HW, Schalij-Delfos NE, Jager MJ. The heterogeneous distribution of monosomy 3 in uveal melanomas: implications for prognostication based on fine-needle aspiration biopsies. Arch Pathol Lab Med 2007; 131:91-96.
38. Onken MD, Worley LA, Dávila RM, Char DH, Harbour JW. Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. J Mol Diagn 2006; 8:567-573.